Inhibrx (INBX) Competitor Comparison
We are evaluating the key criteria listed to compare Inhibrx (INBX) against its competitors in the Biotechnology industry.
Market Capitalization
86 / 368Gross Profits
242 / 278Total Revenue
254 / 300EBITDA
263 / 337Free Cashflow
287 / 352Quick Ratio
85 / 357Earnings per Share
1 / 359Dividend yield
0 / 6Total Cash
97 / 358Performance 3 years
191 / 368Performance 5 years
154 / 368Performance 10 years
126 / 368Linearity 3 years
128 / 368Linearity 5 years
32 / 368Linearity 10 years
23 / 368Total Rank
325 / 368Dividend Rank
162 / 368Valuation Rank
349 / 368Piotroski Rank
291 / 368Muliplier Rank
365 / 368Total Cash - INBX ranking 97 / 358
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.